Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Conditions:   Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Biological: Pembrolizumab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 31, 2019 / by / in
Comments